至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

The MHC Class I Cancer-Associated Neoepitope Trh4 Linked with Impaired Peptide Processing Induces a Unique Noncanonical TCR Conformer.

J. Immunol.. 2016; 
HafstrandIda,DoorduijnElien M,DuruAdil Doganay,BurattoJeremie,OliveiraClaudia Cunha,SandalovaTatyana,van HallThorbald,AchourAd
Products/Services Used Details Operation
Peptide Synthesis The peptide Trh4 (MCLRMTAVM) as well as the norleucine (NLE; MCLR-NLE-TAVM; Trh4-p5NLE) and the α-aminobutyric acid (ABU; M-ABU-LRMTAVM; Trh4-p2ABU) altered peptide variants of Trh4 were purchased from Genscript (Piscataway, NJ). Get A Quote

摘要

MHC class I downregulation represents a significant challenge for successful T cell-based immunotherapy. T cell epitopes associated with impaired peptide processing (TEIPP) constitute a novel category of immunogenic Ags that are selectively presented on transporter associated with Ag processing-deficient cells. The TEIPP neoepitopes are CD8 T cell targets, derived from nonmutated self-proteins that might be exploited to prevent immune escape. In this study, the crystal structure of H-2D(b) in complex with the first identified TEIPP Ag (MCLRMTAVM) derived from the Trh4 protein has been determined to 2.25 Å resolution. In contrast to prototypic H-2D(b) peptides, Trh4 takes a noncanonical peptide-binding pa... More

关键词